Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Finch Therapeutics Group, Inc.FNCH · Entity 90094 | Director | June 13, 2022 | June 15, 2022 |
| Harpoon Therapeutics, Inc.HARP · Entity 11424 | Director | April 01, 2023 | April 04, 2023 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | Director | July 19, 2023 | July 21, 2023 |
| Sionna Therapeutics, Inc.SION · Entity 5996 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Finch Therapeutics Group, Inc.
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2032-06-12 | Direct | 44,843 |
Reported balance
After 2022-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-13 · Grant · Acquired 44,843 · Balance 44,843 F1: The shares subject to this option shall vest in twelve equal monthly installments beginning on July 13, 2022, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in twelve equal monthly installments beginning on July 13, 2022, subject to the Reporting Person continuing to provide service through each such date.
Harpoon Therapeutics, Inc.
Report date April 01, 2023 · Filed April 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,028 |
Reported balance
After 2023-04-01 transaction · row 1
1 source rowRow 1 · 2023-04-01 · Grant · Acquired 21,028 · Balance 21,028 F1: Represents shares of common stock issuable upon the settlement of restricted stock units ("RSUs"). The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $14,375. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon the settlement of restricted stock units ("RSUs"). The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $14,375.
LENZ Therapeutics, Inc.
Report date July 19, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-07-18 | Direct | 20,000 |
Reported balance
After 2023-07-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-19 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
Sionna Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.73 · Expires 2036-06-16 | Direct | 17,340 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 17,340 · Balance 17,340 F1: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pandion Therapeutics, Inc.
Report date April 01, 2021 · Filed April 01, 2021
Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-01 transaction · row 1
1 source rowRow 1 · 2021-04-01 · Other · Disposed 503,254 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. |
| Common StockSEC Table I · non-derivative | IndirectBy husband | 0 |
Reported balance
After 2021-04-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-04-01 · Other · Disposed 1,200 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2030-07-16 | Direct | 0 |
Reported balance
After 2021-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-01 · Disposition to issuer · Disposed 114,876 · Balance 0 F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of immediately prior to the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.75 · Expires 2031-02-07 | Direct | 0 |
Reported balance
After 2021-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-01 · Disposition to issuer · Disposed 73,789 · Balance 0 F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: All options were vested and exercisable as of immediately prior to the Effective Time.
F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:48 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,340 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001816744-26-000002 · edgardoc.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,340 Underlying: Common Stock · 17,340 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:08 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,959 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0002036042-25-000034 · edgardoc.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,959 Underlying: Common Stock · 19,959 shares Expires 2035-06-11 F1 · derivative.exercise_date: This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantStock Option (Right to Buy) · Derivative | 39,919 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017036 · ownership.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,919 Underlying: Common Stock · 39,919 shares Expires 2035-02-05 F1 · derivative.exercise_date: The shares underlying this option vest in three equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:13 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-23-043145 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-18 F1 · derivative.exercise_date: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 21:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantCommon Stock | 21,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022808 · doc4.xml · nonDerivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,028 F1 · shares: Represents shares of common stock issuable upon the settlement of restricted stock units ("RSUs"). The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $14,375. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 22:50 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 37,500 | $1.40 Strike: $2.01 | $52,500.00 |
DisclosureSEC source: 0001209191-22-039329 · doc4.xml · derivative · entry 2 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2032-06-21 F2 · shares: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $52,500 ("Election Option"). F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $52,500 ("Election Option"). F3 · derivative.exercise_date: One-half of the Election Option vested and became exercisable on June 22, 2022, and 25% of each Election Option will vest and become exercisable on each of September 30, 2022 and December 31, 2022, subject to the continuous service of the Reporting Person with the Issuer on each vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 22:50 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-22-039329 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2032-06-21 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 21, 2023, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 21:40 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-22-038736 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 21:02 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | GrantStock Option (right to buy) · Derivative | 44,843 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0000899243-22-022614 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,843 Underlying: Common Stock · 44,843 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve equal monthly installments beginning on July 13, 2022, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:17 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | GrantStock Option (right to buy) · Derivative | 23,419 | $0.00 Strike: $12.27 | $0.00 |
DisclosureSEC source: 0001209191-21-032819 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,419 Underlying: Common Stock · 23,419 shares Expires 2031-05-11 F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option vest on May 12, 2022, and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 04, 2021 Filed May 8, 2021 01:59 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,653 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001209191-21-031110 · doc4.xml · derivative · entry 2 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,653 Underlying: Common Stock · 2,653 shares Expires 2031-05-03 F2 · derivative.exercise_date: 50% of the shares subject to the option are fully vested and exercisable, and 25% will vest and become exercisable on September 30, 2021 and December 31, 2021, subject to the continuous service of the Reporting Person on each vesting date. Read SEC document |
| May 04, 2021 Filed May 8, 2021 01:59 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001209191-21-031110 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2031-05-03 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 4, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| May 04, 2021 Filed May 15, 2021 00:09 UTC Amendment | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 2,571 | $0.00 Strike: $23.20 | $0.00 |
DisclosureSEC source: 0001209191-21-032974 · doc4a.xml · derivative · entry 2 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,571 Underlying: Common Stock · 2,571 shares Expires 2031-05-03 F3 · derivative.exercise_price: This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error related to the calculation date of the Black-Scholes value. F4 · shares: The number of shares underlying the option was erroneously reported as 2,653 on the original Form 4 filed on May 7, 2021 due to an administrative error related to the calculation date of the Black-Scholes value. F5 · derivative.exercise_date: 50% of the shares subject to the option are fully vested and exercisable, and 25% will vest and become exercisable on September 30, 2021 and December 31, 2021, subject to the continuous service of the Reporting Person on each vesting date. Read SEC document |
| May 04, 2021 Filed May 15, 2021 00:09 UTC Amendment | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $23.20 | $0.00 |
DisclosureSEC source: 0001209191-21-032974 · doc4a.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2031-05-03 F1 · derivative.exercise_price: This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error. F2 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:59 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 73,789 | Not disclosed Strike: $17.75 | Not disclosed |
DisclosureSEC source: 0000899243-21-014467 · doc4.xml · derivative · entry 4 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,789 shares Expires 2031-02-07 F3 · price: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of immediately prior to the Effective Time. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:59 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 114,876 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-014467 · doc4.xml · derivative · entry 3 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,876 shares Expires 2030-07-16 F3 · price: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of immediately prior to the Effective Time. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:59 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | OtherCommon Stock | 1,200 | $60.00 | $72,000.00 |
DisclosureSEC source: 0000899243-21-014467 · doc4.xml · nonDerivative · entry 2 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By husband Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 23:59 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | OtherCommon Stock | 503,254 | $60.00 | $30,195,240.00 |
DisclosureSEC source: 0000899243-21-014467 · doc4.xml · nonDerivative · entry 1 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:45 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | GrantStock Option (right to buy) · Derivative | 73,789 | $0.00 Strike: $17.75 | $0.00 |
DisclosureSEC source: 0000899243-21-005684 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,789 Underlying: Common Stock · 73,789 shares Expires 2031-02-07 F1 · derivative.exercise_date: This option award was granted on February 8, 2021. 1/4 of the shares underlying the award shall vest on February 8, 2022, with the remainder of the shares vesting in equal monthly installments following February 8, 2022 through February 8, 2025, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 23:32 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | ConversionSeries B Preferred Stock · Derivative | 107,768 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019860 · doc4.xml · derivative · entry 5 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 23:32 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | PurchaseCommon Stock | 1,200 | $18.00 | $21,600.00 |
DisclosureSEC source: 0000899243-20-019860 · doc4.xml · nonDerivative · entry 2 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By husband Disclosed balance after: 1,200 F2 · shares: Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 23:32 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | ConversionCommon Stock | 21,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019860 · doc4.xml · nonDerivative · entry 1 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 23:32 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | GrantStock Option (right to buy) · Derivative | 58,239 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019860 · doc4.xml · derivative · entry 4 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,239 Underlying: Common Stock · 58,239 shares Expires 2030-07-16 F4 · derivative.exercise_date: This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 23:32 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | GrantStock Option (right to buy) · Derivative | 56,637 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019860 · doc4.xml · derivative · entry 3 Viney Joanne L. · CIK 0001816744 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,637 Underlying: Common Stock · 56,637 shares Expires 2030-07-16 F3 · derivative.exercise_date: This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:49 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (right to buy) · Derivative | 20,335 | $0.00 Strike: $17.49 | $0.00 |
DisclosureSEC source: 0001209191-20-040669 · doc4.xml · derivative · entry 1 Viney Joanne L. · CIK 0001816744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,335 Underlying: Common Stock · 20,335 shares Expires 2030-06-30 F1 · derivative.exercise_date: The stock option vests in three equal annual installments measured from the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.